TD Cowen raised the firm’s price target on Twist Bioscience to $65 from $55 and keeps a Buy rating on the shares. The firm said despite a recent run they see continued upside tothe shares given conservative guidance, visible path to profitability and lineup of FY24 catalysts including Express Gene adoptionand GM improvements.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST:
- Twist publishes study detailing the discovery of TB206-001 targeting A2AR
- Twist extends rally as Wall Street sees opportunity amid GenScript scrutiny
- Twist Bioscience initiated with a Buy at Guggenheim (yesterday)
- Twist Bioscience initiated with a Buy at Guggenheim
- Twist Bioscience price target raised to $48 from $43 at Scotiabank
Questions or Comments about the article? Write to editor@tipranks.com